Estimated reading time: 6 minutes
Key Takeaways
- Sarepta Therapeutics’ shares plunged more than 35 per cent after the FDA requested withdrawal of Elevidys.
- The gene therapy’s use of the AAVrh74 vector is linked to three patient deaths from acute liver failure.
- The FDA imposed a full clinical hold on all AAVrh74 trials, revoking the platform technology designation.
- Sarepta will keep shipping Elevidys to ambulatory patients, rejecting the agency’s request.
- The stock rout erased billions in market value, far outpacing the 1.9 per cent dip in the XBI biotechnology index.
Table of contents
Stock Performance
On 18 July 2025, Sarepta Therapeutics shares cratered to $13.90 by mid-afternoon, a fall of more than 35 per cent from the prior close. The sell-off deepened over the next three sessions, with the stock touching $12.80 on 21 July, a cumulative 43 per cent decline from the 17 July open of $22.54. “It’s the single worst day for the gene-therapy space since 2018,” one trader remarked, noting that the broader XBI biotechnology index slipped just 1.9 per cent.
Why the FDA Moved
Citing an “unreasonable and significant risk” to patients, the FDA’s Center for Biologics Evaluation and Research asked Sarepta to voluntarily withdraw Elevidys. The trigger: three deaths from acute liver failure in patients exposed to therapies that use the AAVrh74 vector, including Elevidys. Internal FDA memos, seen by industry lawyers, warned that additional cases could surface without immediate action.
Sarepta’s Response
Sarepta rejected the withdrawal request, asserting that no new safety signal has emerged in ambulatory Duchenne patients. The company will continue to supply Elevidys under its current label, while shipments to non-ambulant patients remain paused. In a statement, management insisted, “Patient safety is our top priority,” and pledged to work with regulators on enhanced monitoring, updated labeling, and a potential risk-evaluation strategy.
Safety Concerns & Clinical Hold
- All ongoing trials using the AAVrh74 vector—including those for limb-girdle muscular dystrophy—have been placed on full clinical hold.
- FDA investigators linked each fatal case to acute liver failure within four to six weeks of infusion.
- Enhanced patient monitoring, liver-function surveillance, and fresh pre-clinical toxicology studies may be mandatory before any restart.
Platform Designation Revoked
Until now, the AAVrh74 vector enjoyed an FDA “platform technology” status—an administrative shortcut that let Sarepta file data across multiple indications simultaneously. That designation has been stripped, creating new regulatory hurdles for every pipeline asset built on the vector.
Regulatory Actions
Beyond the withdrawal request, the FDA ordered an immediate halt to commercial supply for non-ambulant patients, paused investigator-led studies, and froze compassionate-use programs. Analysts at Morgan Stanley called the move “one of the toughest gene-therapy crackdowns in recent memory.”
Shareholder Impact & Financials
The market rout wiped an estimated $4 billion off Sarepta’s market cap. Lost Elevidys revenue, suspended trials, and potential litigation tied to patient deaths are expected to depress 2025–2026 earnings. Some analysts now model a capital raise by mid-2026 to bridge the cash gap.
Outlook
Sarepta faces a defining period. Management must satisfy FDA safety concerns, rebuild clinician trust, and reassure investors that its gene-therapy ambitions remain viable. Alternatives—such as new viral vectors or modified dosing regimens—are on the table, but until regulatory clarity emerges, the stock is likely to trade at a risk discount.
FAQs
Why did the FDA ask for Elevidys to be withdrawn?
The agency linked three deaths from acute liver failure to treatments using the AAVrh74 vector and deemed the risk “unreasonable and significant.”
Is Elevidys still available to patients?
Yes, but only for ambulatory Duchenne patients. Shipments to non-ambulant patients are paused while Sarepta negotiates new safety measures.
What happens to ongoing clinical trials?
All studies using the AAVrh74 vector are on full clinical hold. Restarting them will likely require additional toxicology data and stricter monitoring.
How severe is the financial hit for Sarepta?
Analysts estimate a multiyear revenue shortfall plus potential legal liabilities. A fresh capital raise may be needed if trials remain suspended well into 2026.
Could other gene-therapy companies be affected?
Yes. The FDA’s aggressive stance may set a precedent, leading to tighter oversight of all AAV-based therapies in development.
